[1]刘欢 周金花.静脉动脉-体外膜肺氧合在肺动脉高压治疗中的研究进展[J].心血管病学进展,2024,(11):1016.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.013]
 LIU Huan,ZHOU Jinhua.Venoarterial Extracorporeal Membrane Oxygenation in the Treatment of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2024,(11):1016.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.013]
点击复制

静脉动脉-体外膜肺氧合在肺动脉高压治疗中的研究进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年11期
页码:
1016
栏目:
综述
出版日期:
2024-11-25

文章信息/Info

Title:
Venoarterial Extracorporeal Membrane Oxygenation in the Treatment of Pulmonary Hypertension
作者:
刘欢1 周金花 2
(1.济宁市第一人民医院急诊内科,山东 济宁 272000;2. 济宁市第一人民医院呼吸与危重症医学科,山东 济宁 272000)
Author(s):
LIU Huan1ZHOU Jinhua2
(1.Department of Emergency Internal Medicine,Jining No.1 People’s Hospital,Jining 272000,Shandong,China; 2. Department of Pulmonary and Critical Care Medicine,Jining No.1 People’s Hospital,Jining 272000,Shandong,China)
关键词:
静脉动脉-体外膜肺氧合肺动脉高压体外循环技术
Keywords:
Venoarterial extracorporeal membrane oxygenation Pulmonary hypertensionExtracorporeal circulation technique
DOI:
10.16806/j.cnki.issn.1004-3934.2024.11.013
摘要:
静脉动脉-体外膜肺氧合(VA-ECMO)是一项用于治疗严重心肺功能障碍患者的体外循环技术。它通过模拟心肺功能,提升血氧水平,减轻心脏负荷,在处理肺动脉高压方面发挥着重要作用。作为一种临时生命支持手段,可对心肺功能衰竭的肺动脉高压患者进行短期治疗,延长治疗时间,推动病情好转,为肺血管修复和重建提供契机。VA-ECMO在不同类型的肺动脉高压中均扮演着重要角色,有助于挽救患者生命,减少永久性心肺功能损伤。现对VA-ECMO在肺动脉高压治疗方面的研究进展进行综述。
Abstract:
Venoarterialextracorporeal membrane oxygenation (VA-ECMO) is an extracorporeal circulation technique used to treat patients with severe cardiopulmonary dysfunction. It simulates the functions of the heart and lungs,increases blood oxygen levels ,reduces cardiac workload,and plays an important role in managing pulmonary hypertension. As a temporary life support measure,it provides short-term treatment for pulmonary hypertension in patients with cardiopulmonary failure,prolongs treatment time,promotes improvement in the condition,and provides an opportunity for pulmonary vascular repair and reconstruction. VA-ECMO plays a significant role in various types of pulmonary hypertension,helping to save patients’ lives and reduce permanent cardiopulmonary functional damage. This article reviews the research progress of VA-ECMO in the treatment of pulmonary hypertension

参考文献/References:

[1].Wrisinger WC,Thompson SL. Basics of extracorporeal membrane oxygenation[J].Surg Clin North Am,2022,102(1):23-35.
[2].Sniderman J,MacLaren G. Pulmonary hypertension and extracorporeal membrane oxygenation—Disparate causes,worse outcomes[J].?Pediatr Crit Care Med,2020,21(3):294-295.
[3].Brodie D,Slutsky AS,Combes A. Extracorporeal life support for adults with respiratory failure and related indications:a review[J].?JAMA,2019,322(6):557-568.
[4].Barbaro RP,MacLaren G,Boonstra PS,et al. Extracorporeal membrane oxygenation support in COVID-19:an international cohort study of the Extracorporeal Life Support Organization registry published correction appears in Lancet[J]. Lancet,2020,396(10257):1071-1078.
[5].Barbaro RP,MacLaren G,Boonstra PS,et al. Extracorporeal membrane oxygenation for COVID-19:evolving outcomes from the international Extracorporeal Life Support Organization Registry[J].?Lancet,2021,398(10307):1230-1238.
[6].Kapur NK. Innovating to resolve the pressure-oxygenation-paradox created by VA-ECMO could improve outcomes for acute myocardial infarction and cardiogenic shock[J]. J Heart Lung Transplant,2024,43(5):700-702.
[7].Guglin M,Zucker MJ,Bazan VM,et al. Venoarterial ECMO for adults:JACC Scientific Expert Panel[J].?J Am Coll Cardiol,2019,73(6):698-716.
[8].Rao P,Khalpey Z,Smith R,et al. Venoarterial extracorporeal membrane oxygenation for cardiogenic shock and cardiac arrest[J].?Circ Heart Fail,2018,11(9):e004905.
[9].Kiziltug H,Falter F. Circulatory support during lung transplantation[J].?Curr Opin Anaesthesiol,2020,33(1):37-42.
[10].Singh V,Singh G,Arya RC,et al. Vascular access complications in patients undergoing veno-arterial ecmo and their impact on survival in patients with refractory cardiogenic shock:A retrospective 8-year study[J]. Ann Card Anaesth,2022,25(2),171-177.
[11].Gao X,Ninan J,Bohman JK,et al. Extracorporeal membrane oxygenation and acute kidney injury:a single-center retrospective cohort[J].?Sci Rep,2023,13(1):15112.
[12].Rajagopal K,Cheema FH,Omer S. Commentary:Brain damage during extracorporeal membrane oxygenation support:Looking where the light is![J]. J Thorac Cardiovasc Surg,2023,165(6):2112-2113.
[13].Johnson S,Sommer N,Cox-Flaherty K,et al. Pulmonary hypertension: a contemporary review[J].?Am J Respir Crit Care Med,2023,208(5):528-548.
[14].Kelava M,Koprivanac M,Smedira N,et al. Extracorporeal membrane oxygenation in pulmonary endarterectomy patients[J].?J Cardiothorac Vasc Anesth,2019,33(1):60-69.
[15].Sugiyama K,Suzuki S,Fujiyoshi T,et al. Extracorporeal membrane oxygenation after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension[J].?J Card Surg,2019,34(6):428-434.
[16].Delcroix M,de Perrot M,Ja?s X,et al. Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management[J]. Lancet Respir Med,2023,11(9):836-850.
[17].Mullin CJ,Klinger JR. Chronic thromboembolic pulmonary hypertension[J].?Heart Fail Clin,2018,14(3):339-351.
[18].Otani N,Watanabe R,Tomoe T,et al. Pathophysiology and treatment of chronic thromboembolic pulmonary hypertension[J].?Int J Mol Sci,2023,24(4):3979.
[19].Long F,Luo M,Qin Z,et al. Secondary left heart failure occurred during VA-ECMO assistance for severe residual pulmonary hypertension after pulmonary endarterectomy:a case report[J].?BMC Anesthesiol,2021,21(1):317.
[20].Vaidy A,Vaidya A. Pulmonary arterial hypertension in pregnancy[J].?Curr Opin Cardiol,2023,38(3):250-256.
[21].Vitulo P,Beretta M,Martucci G,et al. Challenge of pregnancy in patients with pre-capillary pulmonary hypertension:veno-arterial extracorporeal membrane oxygenation as an innovative support for delivery[J].?J Cardiothorac Vasc Anesth,2017,31(6):2152-2155.
[22].Sankaran D,Lakshminrusimha S. Pulmonary hypertension in the newborn—Etiology and pathogenesis[J].?Semin Fetal Neonatal Med,2022,27(4):101381.
[23].Song S,Park KH,Lee H,et al. Veno-arterial extracorporeal membrane oxygenation for the treatment of persistent pulmonary hypertension in the newborn[J].?Asian J Surg,2023,46(2):1145-1146.
[24].Hu H,Jing X,Duan X,et al. Congenital diaphragmatic hernia[J].?Pediatr Pulmonol,2023,58(9):2666-2667.
[25].Stewart LA,Klein-Cloud R,Gerall C,et al. Extracorporeal membrane oxygenation (ECMO) and its complications in newborns with congenital diaphragmatic hernia[J].?J Pediatr Surg,2022,57(8):1642-1648.
[26].O’Connor E,Tamura R,Hannon T,et al. Congenital diaphragmatic hernia survival in an English regional ECMO center[J]. World J Pediatr Surg,2023,6(2):e000506.
[27].Messika J,Eloy P,Boulate D,et al. Protocol for venoarterial ExtraCorporeal Membrane Oxygenation to reduce morbidity and mortality following bilateral lung TransPlantation:the ECMOToP randomised controlled trial[J]. BMJ Open,2024,14(3):e077770.
[28].St?cel T,Kegler K,M?drala A,et al. Lung transplantation in patients with pulmonary hypertension with extracorporeal membrane oxygenation (ECMO) support:5-year experience[J]. Transplant Proc,2024,56(4):898-903.
[29].St?cel T,Antończyk R,Latos M,et al. Extracorporeal membrane oxygenation as a postoperative left ventricle conditioning tool after lung transplantation in patients with primary pulmonary artery hypertension:first Polish experience[J].?Transplant Proc,2020,52(7):2113-2117.
[30].Blakeslee-Carter J,Shao C,LaGrone R,et al. Vascular complications based on mode of extracorporeal membrane oxygenation[J]. J Vasc Surg,2022,75(6):2037-2046.
[31].Nunez JI,Gosling AF,O’Gara B,et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation:an ELSO registry analysis[J].?Intensive Care Med,2022,48(2):213-224.
[32].Bartlett R,Arachichilage DJ,Chitlur M,et al. The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation[J]. Semin Thromb Hemost,2024,50(1):81-90.
[33].Biffi S,Di Bella S,Scaravilli V,et al. Infections during extracorporeal membrane oxygenation:epidemiology,risk factors,pathogenesis and prevention[J].?Int J Antimicrob Agents,2017,50(1):9-16.
[34].Pe?a-López Y,Machado MC,Rello J. Infection in ECMO patients:changes in epidemiology,diagnosis and prevention[J]. Anaesth Crit Care Pain Med,2024,43(1):101319.
[35].Minc SD,Hayanga HK,Thibault D,et al. Vascular complications increase hospital charges and mortality in adult patients on extracorporeal membrane oxygenation in the United States [J].?Semin Thorac Cardiovasc Surg,2021,33(2):397-406.
[36].Shigemura N,Kehara H,Toyoda Y. Peripheral veno-arterial extracorporeal membrane oxygenation during lung transplantation with special reference to differential hypoxemia and vascular complications[J]. J Thorac Dis,2024,16(1):798-803.
[37].Chen YC,Tsai FC,Fang JT,et al. Acute kidney injury in adults receiving extracorporeal membrane oxygenation[J].?J Formos Med Assoc,2014,113(11):778-785.
[38].Guru PK,Balasubramanian P,Ghimire M,et al. Acute kidney injury in patients before and after extracorporeal membrane oxygenation (ECMO)—Retrospective longitudinal analysis of the hospital outcomes[J]. J Crit Care,2024,81:154528.
[39].Chapman JT,Breeding J,Kerr SJ,et al. CNS complications in adult patients treated with extracorporeal membrane oxygenation[J].?Crit Care Med,2021,49(2):282-291.
[40].Cho SM,Canner J,Chiarini G,et al. Modifiable risk factors and mortality from ischemic and hemorrhagic strokes in patients receiving venoarterial extracorporeal membrane oxygenation:results from the Extracorporeal Life Support Organization Registry[J].?Crit Care Med,2020,48(10):e897-e905.

相似文献/References:

[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
 MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(11):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
 ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(11):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
 WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(11):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
 WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(11):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
 DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(11):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
 ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
 ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
 HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
 LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
 Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(11):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]

更新日期/Last Update: 2024-12-02